Difference between revisions of "Uveal melanoma medical therapy"

Jump to: navigation, search
(3 intermediate revisions by the same user not shown)
Line 3: Line 3:
 
{{CMG}}{{AE}}{{Fs}}, {{Simrat}}
 
{{CMG}}{{AE}}{{Fs}}, {{Simrat}}
 
==Overview==
 
==Overview==
+
Pharmacologic medical therapy is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] [[disease]] and include [[chemotherapy]], [[immunotherapy]], and [[targeted therapy]].
 +
 
 
==Medical Therapy==
 
==Medical Therapy==
 +
Pharmacologic medical [[therapy]] is recommended among [[Patient|patients]] with [[Metastasis|metastatic]] disease:<ref name="pmid29497459">{{cite journal |vauthors=Yang J, Manson DK, Marr BP, Carvajal RD |title=Treatment of uveal melanoma: where are we now? |journal=Ther Adv Med Oncol |volume=10 |issue= |pages=1758834018757175 |date=2018 |pmid=29497459 |pmc=5824910 |doi=10.1177/1758834018757175 |url=}}</ref>
 +
 +
*[[Chemotherapy]]
 +
**[[Dacarbazine]]
 +
**[[Temozolomide]]
 +
**[[Cisplatin]]
 +
**[[Treosulfan]]
 +
**[[Fotemustine]]
 +
*[[Immunotherapy]]
 +
** Checkpoint blockade
 +
***[[Pembrolizumab]]
 +
***[[Ipilimumab]] + [[nivolumab]]
 +
***[[Ipilimumab]] + [[nivolumab]]
 +
***[[Ipilimumab]] + radioembolization
 +
***[[Ipilimumab]] + [[nivolumab]] +radioembolization
 +
** TILs (tumor-infiltrating lymphocytes)
 +
**[[T cell]] redirection
 +
**[[Antibody]]–[[drug]] conjugate
 +
*** Glembatumumab vedotin
 +
*[[Targeted therapy]]
 +
**[[Protein kinase C|PKC]] ([[protein kinase C]])/ MEK
 +
*** AEB071 + BYL719
 +
*** Intermittent selumetinib
 +
*** Selumetinib +/– [[paclitaxel]]
 +
***[[Binimetinib]] + AEB071
 +
** Multi-kinase inhibition
 +
***[[Sorafenib]] (STREAM)
 +
***[[Cabozantinib]] versus [[temozolomide]]/ [[dacarbazine]]
 +
** Epigenetic therapy
 +
***[[Histone deacetylase 2|HDAC]] ([[histone deacetylase]]) inhibition
 +
****[[Vorinostat]]
 +
****[[Pembrolizumab]] + entinostat (PEMDAC)
 +
*** BET (bromodomain and extra-terminal motif) inhibition
 +
** Liver-directed therapy
 +
*** IHP (isolated [[hepatic]] perfusion)
 +
*** PHP ( <br />
 +
 
== References ==  
 
== References ==  
 
{{reflist|2}}
 
{{reflist|2}}

Revision as of 03:24, 16 August 2019

Uveal melanoma Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Uveal melanoma from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X Ray

Echocardiography and Ultrasound

CT

MRI

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Uveal melanoma medical therapy On the Web

Most recent articles

cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Uveal melanoma medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Uveal melanoma medical therapy

CDC on Uveal melanoma medical therapy

Uveal melanoma medical therapy in the news

Blogs on Uveal melanoma medical therapy

to Hospitals Treating Uveal melanoma

Risk calculators and risk factors for Uveal melanoma medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]Associate Editor(s)-in-Chief: Fahimeh Shojaei, M.D., Simrat Sarai, M.D. [2]

Overview

Pharmacologic medical therapy is recommended among patients with metastatic disease and include chemotherapy, immunotherapy, and targeted therapy.

Medical Therapy

Pharmacologic medical therapy is recommended among patients with metastatic disease:[1]

References

  1. Yang J, Manson DK, Marr BP, Carvajal RD (2018). "Treatment of uveal melanoma: where are we now?". Ther Adv Med Oncol. 10: 1758834018757175. doi:10.1177/1758834018757175. PMC 5824910. PMID 29497459.

Linked-in.jpg